atypical haemolytic uraemic syndrome
Haematology · 2013–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ravulizumab Atypical haemolytic uraemic syndrome (aHUS). Treatment of patients with active and progressing thrombotic microangiopathy caused by aHUS. | Jul 2023 | Deferred | 14 individuals |
| eculizumab Prophylactic treatment to prevent atypical haemolytic uraemic syndrome (aHUS) recurrence and thrombotic microangiopathy (TMA) in patients with end-stage renal… | Mar 2018 | Not recommended | input received |
| eculizumab Treatment of atypical Haemolytic Uraemic Syndrome (aHUS). The submission concerns continuation and re-commencement criteria for PBS-subsidised therapy after an… | Aug 2014 | Noted | no section in document |
| eculizumab Treatment of atypical haemolytic uraemic syndrome (aHUS) with confirmed ADAMTS-13 activity >5% (or >10% per PBAC recommendation) and where Shiga-toxin… | Mar 2014 | Recommended with restriction | no section in document |
| eculizumab Treatment of atypical haemolytic uraemic syndrome (aHUS), a rare condition causing thrombotic microangiopathy with end-organ ischaemia and infarction. | Mar 2013 | Not recommended | unclear |
What the PBS pays
$143M in government benefit over 2024–25, across 2,593 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ravulizumab | $105.7M |
| eculizumab | $37.1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| ravulizumabRavulizumab for treating atypical haemolytic uraemic syndrome | TA710 | recommended | 2021-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.